A Phase 3 interventional study of Celecoxib and Celecoxib in Spondylitis, Ankylosing, sponsored by Pfizer. Completed at 47 sites in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2008-04-10.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Spondylitis, Ankylosing by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Spondylitis, Ankylosing · Pfizer.
Among the 34 studies in Spondylitis, Ankylosing by Pfizer, this one is the 2nd largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2003, is one of 7 in phase 3, and was the 14th registered.
533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.
Browse Spondylitis, Ankylosing studies →1 of the 34 studies in Spondylitis, Ankylosing by Pfizer is open now, in 1 country. Recruiting first, the newest first:
Pfizer · Sites in Korea, Republic of
Ages 18+
By country, each count listing its studies:
Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 458 is above the median of 88 across 303 interventional studies indexed under Spondylitis, Ankylosing.
Median enrollment 129 across the 18 interventional studies, 276 across the 16 observational. Of the 33 that completed or were terminated, 21 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 34 studies in Spondylitis, Ankylosing by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the safety and efficacy of once-daily and twice-daily celecoxib versus diclofenac for the treatment of ankylosing spondylitis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Celecoxib
Drug: Celecoxib
Drug: Diclofenac
200 mg oral capsule once daily for 12 weeks
200 mg oral capsule twice daily for 12 weeks
75 mg oral capsule twice daily for 12 weeks
Change from baseline in global pain intensity as assessed by visual analog scale (VAS)
Time frame: Week 12
Responder rates, defined as 50% improvement in VAS from baseline
Time frame: Week 12
Patient's and physician's global assessment of disease activity
Time frame: Weeks 1, 2, 6, and 12
Spinal pain
Time frame: Weeks 1, 2, 6, and 12
Short Form-12
Time frame: Weeks 1, 2, 6, and 12
Adverse events
Time frame: Week 12
Physical evaluation
Time frame: Week 12
Laboratory tests
Time frame: Week 12
Nocturnal pain
Time frame: Weeks 1, 2, 6, and 12
Composite Bath Ankylosing Spondylitis Disease Activity Index
Time frame: Weeks 1, 2, 6, and 12
Bath Ankylosing Spondylitis Metrology Index
Time frame: Weeks 1, 2, 6, and 12
Change from baseline in C-reactive protein measurement
Time frame: Week 12
Responder rates, defined as 50% improvement in VAS from baseline
Time frame: Weeks 1, 2, and 6
Mobility parameters
Time frame: Weeks 1, 2, 6, and 12
Change from baseline in Assessments in Ankylosing Spondylitis 20 score
Time frame: Weeks 1, 2, 6, and 12
Change from baseline in global pain intensity
Time frame: Weeks 1, 2, and 6
Bath Ankylosing Spondylitis Functional Index
Time frame: Weeks 1, 2, 6, and 12
The record gives a start of Jan 2003 and a completion of Jan 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib